Jim Campbell, MD, MS, named IDCRC Leadership Group (LG) Vice-Chair
The IDCRC Leadership Group (LG) is pleased to announce that James (Jim) Campbell, MD, MS, has accepted the position of Leadership Group (LG) vice-chair, effective May 2024. This appointment comes as Kathleen Neuzil, MD, MPH, FIDSA, recently stepped down as LG co-chair to become the director of the Fogarty International Center and NIH associate director for international research.
"We are extremely excited to welcome Jim Campbell to the IDCRC leadership team. Jim is an outstanding pediatrician, clinical investigator, academic leader, and colleague. We look forward to working with him," says David S. Stephens, MD, IDCRC PI and Leadership Group chair.
Dr. Campbell is a professor in the Department of Pediatrics at the University of Maryland School of Medicine and is currently serving as interim head of the Division of Infectious Diseases and Tropical Pediatrics. He also serves as vice chair of the Institutional Review Board, director of the University of Maryland Baltimore Clinical Research Training and Mentoring Program, and vice chair of the Committee on Infectious Diseases (COID or “Red Book Committee”) for the American Academy of Pediatrics.
As a member of UMB’s Center for Vaccine Development and a highly accomplished physician-scientist, Dr. Campbell is also involved in several research endeavors and has led clinical trials of many vaccines and epidemiologic investigations of vaccine-preventable diseases, including Neisseria meningitidis, Bacillus anthracis, seasonal influenza, pandemic influenza, smallpox, and others.
Dr. Campbell will join David Stephens, MD, (Contact PI, LG chair), Monica Farley, MD, (LOC co-director), and Jodie Dionne, MD, (LOC co-director), as part of the core leadership team of the LG, overseeing all LG operations, as the IDCRC continues to serve as a highly collaborative network implementing IDCRC/NIAID-priority clinical research.
“We are all excited to have Jim join the IDCRC leadership group. His broad-based experience in pediatrics, clinical trials, global health, and vaccine policy will benefit our leadership team immensely. Kathy Neuzil is hard to replace but we can’t think of anyone better prepared to take on this important role,” says Monica Farley, MD, and Jodie Dionne, MD, MSPH, LOC Co-Directors.